Skip to content
VYGR·Nasdaq·US

Voyager Therapeutics

Voyager Therapeutics is a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, and other central nervous system diseases, developed both independently and with licensees and collaborators including Alexion, AstraZeneca Rare Disease, Novartis Pharma AG, Neurocrine Biosciences, and Transition Bio.

Source: SEC 10-K Mar 9, 2026

Thematic Position

VYGR

Relationship Groups

Partners4
Licensing4
Competitors16

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

26 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

tax restrictionownership change limitation
IRC Sections 382/383 restrict use of net operating loss carryforwards after ownership change
SEC 10-KMar 9, 2026

The full regulatory passage is part of the Pro plan.

10 more · Regulatory and geopolitical insights are part of the Pro plan.